Literature DB >> 32427929

Adjuvant and ablative therapies for low-risk UTUC: avenues to enhance kidney preservation.

Jay D Raman1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32427929     DOI： 10.1038/s41585-020-0338-4

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Letter to the Editor RE: Okeke and Rai. Editorial Comment on: Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Center Prospective Nonrandomized Trial by Gallioli et al. (From: Okeke Z and Rai A. J Endourol 2020;34:573-580; DOI: 10.1089/end.2019.0750).

Authors:  Angelo Territo; Andrea Gallioli; Alberto Breda
Journal:  J Endourol       Date:  2020-07-08       Impact factor: 2.942

2.  Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.

Authors:  Nir Kleinmann; Surena F Matin; Phillip M Pierorazio; John L Gore; Ahmad Shabsigh; Brian Hu; Karim Chamie; Guilherme Godoy; Scott Hubosky; Marcelino Rivera; Michael O'Donnell; Marcus Quek; Jay D Raman; John J Knoedler; Douglas Scherr; Joshua Stern; Christopher Weight; Alon Weizer; Michael Woods; Hristos Kaimakliotis; Angela B Smith; Jennifer Linehan; Jonathan Coleman; Mitchell R Humphreys; Raymond Pak; David Lifshitz; Michael Verni; Mehrad Adibi; Mahul B Amin; Elyse Seltzer; Ifat Klein; Marina Konorty; Dalit Strauss-Ayali; Gil Hakim; Mark Schoenberg; Seth P Lerner
Journal:  Lancet Oncol       Date:  2020-04-29       Impact factor: 41.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.